GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
G

Gene One Life Science 011000.KS · KRW

Health Care · KRX · 🇰🇷 South Korea

Compare

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Gene One Life Science

Its shares trade on KRX under the ticker 011000.KS. It has been listed since 16 November 1987. In the fiscal year to 31 December 2025, it reported revenue of ₩23.93bn and a net loss of ₩47.66bn. At that date it held total assets of ₩119.21bn and shareholders' equity of ₩40.90bn.

GeneOne Life Science, Inc. engages in the research, development, and manufacture of deoxyribonucleic acid (DNA) vaccines for the prevention and treatment of diseases. The company is headquartered in Seoul, Seoul. The firm is a biomedical contract manufacturing organization (CMO). Its textile business engages in the provision of wicks under the brand name of INTERON, which are used in dress shirts, suits and caps. Its biopharmaceutical business engages in the research, development and manufacture of biomedical, plasmid deoxyribonucleic acid (DNA) and DNA vaccines. The company also engaged in the leasing of nonresidential buildings.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
16 Nov 1987
Website
genels.com ↗

Leadership

Pay as last reported

  • Mr. Yeong Geun ParkChief Executive Officer, Director, since 2006₩2.77bn
  • Mr. Byeong Mun ChoManaging Director, since 2009₩657.0m
  • Mr. Seong Ho ChoiInternal Auditor
  • Mr. Sang Don KimNon-Executive Independent Director
  • Han Mo ParkIR Contact Officer

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Headquartered in Seoul, South Korea
  • Engages in DNA vaccine research and development
  • Operates as a biomedical contract manufacturing organization

Weaknesses

  • Textile business provides wicks under the brand INTERON
  • Leasing of nonresidential buildings is a secondary activity
  • Biopharmaceutical business includes plasmid DNA and DNA vaccines

Opportunities

  • Expansion of DNA vaccine market in healthcare sector
  • Growth potential in biotechnology industry
  • Potential for increased biopharmaceutical research funding

Threats

  • Reliance on textile business for revenue
  • Competition in biopharmaceutical manufacturing
  • Regulatory challenges in DNA vaccine development

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.